COVID Boosters Should Target Omicron BA.4/5
An FDA vaccine advisory committee recommended future COVID-19 vaccine boosters should include a SARS-CoV-2 omicron BA.4/5 component for boosters beginning in fall 2022.
Category: Other Infections
Other Infections
Latest
Other Infections
Latest
Positive Phase III Data for GSK RSV Vaccine Candidate
A phase III trial investigating the GSK RSV vaccine candidate for adults aged 60 years and above exceeded its primary endpoint with no unexpected safety concerns observed, the company announced.
Other Infections
Latest
Patient Safety Group Calls for COVID Booster Schedule
The most effective way to maintain public health as COVID-19 becomes endemic is to move towards a regular COVID booster schedule, according to patient safety organization ECRI.
FDA Expands Authorization of Pfizer COVID Booster to Kids 5-through-11
Children age 5-through-11 are now authorized to receive the Pfizer COVID booster at least five months after completion of their primary two-dose series of the Pfizer vaccine.
Read More
FDA Authorizes First COVID-Flu-RSV Test Without a Prescription
The US FDA authorized use of the Labcorp Seasonal Respiratory Virus RT-PCR DTC Test — the first COVID-Flu-RSV test without the need for a prescription.
Read More
Genetics May Play a Role in Managing Stress of COVID-19 Pandemic
Some individuals managed the stress of the COVID-19 pandemic better than others, in part, due to their genetics, according to a new study published in Plos Genetics.
Read More
FDA Approves Olumiant for Hospitalized COVID Patients
The FDA approved Olumiant (baricitinib) for hospitalized adults with COVID-19 requiring supplemental oxygen, noninvasive or invasive mechanical ventilation, or ECMO.
Read More
FDA Warns Against Use of Skippack Medical COVID Antigen Tests
The US FDA is warning consumers and healthcare providers to not use the Skippack Medical Lab SARS-CoV-2 Antigen Rapid Test (Colloidal Gold) because these tests are not authorized, cleared, or approved by the FDA.
Read More
COVID Vaccine Induces Multiple Immune Responses
While COVID vaccine-induced neutralizing antibody responses protect against SARS-CoV-2 infection, control of viral replication is mediated by responses that involve T cells and the antibody-binding Fc receptor.
Read More
Are Rapid Antigen COVID Tests Useful for Variants?
While rapid antigen COVID tests remain a useful tool for the detection of COVID-19 infections, continuous assessment and updating is likely needed in the context of variants of concern.
Read More
Serious Neurologic Symptoms Present in 13% of Hospitalized COVID-19 Patients
Nearly 13% of patients admitted for COVID-19 in the first year of the pandemic developed serious...
Read More
Success of Noninvasive Respiratory Support in COVID Patients May Be Tied to Work of Breathing
Computational modeling shows that noninvasive respiratory support is more likely to be successful if it allows significant reductions in patients’ breathing efforts.
Read More
Long COVID: 60% of Patients Have Symptoms a Year Later
Six-in-ten people with COVID-19 still have at least one symptom a year later, according to a new study being presented at this year’s European Congress of Clinical Microbiology & Infectious Diseases meeting.
Read More
Asthma Drug Montelukast Can Block Crucial SARS-CoV-2 Protein
Asthma and allergy drug montelukast (Singulair) can bind to and block a protein produced by the virus SARS-CoV-2 and reduce viral replication.
Read More
High-flow Oxygen for Severe COVID-19
Emerging research shows that high-flow oxygen therapy could be enough support for many COVID-19 patients through to recovery.
Read More